Arsenal Acquires Synchrogenix
Search

Arsenal Acquires Synchrogenix

synch nf1Arsenal Capital Partners has acquired Synchrogenix, a provider of regulatory writing services to the pharmaceutical industry.  Upon closing, Synchrogenix was merged into Arsenal’s existing portfolio company Certara, a drug development and drug safety consultancy acquired by Arsenal this past December.

“Having worked with our talented staff to build Synchrogenix from the ground up, I was looking for a like-minded company that shared our strong work ethic and focus on excellent customer service and high-quality results. We have found a great match in Arsenal and Certara, and I look forward to expanding the range of services that we offer to all of our customers,” said Synchrogenix CEO Ellen Barrosse.  Ms. Barrosse will remain the CEO of Synchrogenix following the transaction.

Synchrogenix provides regulatory writing services to pharmaceutical, biotechnology, and medical device companies worldwide.  The company provides pre-clinical, clinical, CMC (chemistry, manufacturing and control) and drug safety writing, and global regulatory submission services.  Synchrogenix has more than 50 permanent regulatory writers and editors on staff, located in seven offices in North America, Europe, and Asia. The company is headquartered in Wilmington, DE (www.synchrogenix.com).

mclean nf1“Pharmaceutical companies are looking for greater value and increased synergies from their outsourcing partners,” said Stephen McLean, a Partner at Arsenal and Co-Head of the firm’s Healthcare Group.  “Adding the complementary services Synchrogenix offers to the Certara portfolio will allow Certara to provide its preclinical and clinical pharmacology customers with end-to-end drug development consulting and writing services, including preparation of regulatory submissions such as the Biologic License Application, Investigational New Drug and New Drug Applications.”

Certara offers drug development and data analytics technology and services to the biopharmaceutical research and development market. The company has more than 225 employees located at offices in the US, UK, Canada, and Japan and is headquartered in St. Louis (www.certara.com).

deieso nf1“We were attracted to Synchrogenix by the quality of its work, its outstanding reputation and the global network of regulatory experts that it has developed,” said Donald Deieso, Ph.D. an Operating Partner at Arsenal and Co-Head of the Healthcare Group.  “By combining the most sophisticated regulatory professional organization with the world’s leading computational drug development capabilities, we believe that Certara can continue to enable our clients to improve the pace of efficacious drug development for the benefit of patients around the world.”

Arsenal Capital Partners invests in middle-market specialty industrial and healthcare companies that have $50 million to $250 million in enterprise value. Industries of specific interest include specialty & fine chemicals; segments of healthcare; transportation and logistics; power generation; aerospace & defense; and process industry components and services. Arsenal has $1.7 billion of committed capital under management. The firm was founded in 2000 and has offices in New York and Shanghai (www.arsenalcapital.com).

© 2014 PEPD • Private Equity’s Leading News Magazine • 4-17-14

To search in site, type your keyword and hit enter